<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03972358</url>
  </required_header>
  <id_info>
    <org_study_id>8002</org_study_id>
    <nct_id>NCT03972358</nct_id>
  </id_info>
  <brief_title>Assessing Medical Menstrual Regulation in the United States</brief_title>
  <official_title>Assessing Acceptability and Use of Medical Menstrual Regulation in the United States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynuity Health Projects</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gynuity Health Projects</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the acceptability and use of medical menstrual regulation among women
      in the United States.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Medical menstrual regulation (MMR) entails the use of uterine evacuation medications by women
      with late menses without confirming pregnancy status. Provision of MMR in the United States
      could expand reproductive choice and service options for women. This study will collect data
      on the acceptability, efficacy, safety and feasibility of MMR among women with missed menses
      of 1-21 days
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who report that MMR was acceptable or highly acceptable during the exit interview</measure>
    <time_frame>Up to 28 days after mifepristone administration</time_frame>
    <description>Acceptability of MMR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants not pregnant at follow-up</measure>
    <time_frame>Up to 28 days after mifepristone administration</time_frame>
    <description>Efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events and/or side effects</measure>
    <time_frame>Up to 28 days after mifepristone administration</time_frame>
    <description>Safety and side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived advantages and disadvantages of MMR as reported by participants during the exit interview</measure>
    <time_frame>Up to 28 days after mifepristone administration</time_frame>
    <description>Experiences, perceived advantages and disadvantages</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">284</enrollment>
  <condition>Menstrual Regulation</condition>
  <arm_group>
    <arm_group_label>Medical menstrual regulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mifepristone 200 mg orally on day 1.
Misoprostol 800 mcg buccally on day 2 (24 hours after mifepristone).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <description>All participants will receive 200 mg mifepristone, to be taken orally on day 1.</description>
    <arm_group_label>Medical menstrual regulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>All participants will receive 800 mcg misoprostol, to be taken buccally 24 hours after mifepristone (day 2)</description>
    <arm_group_label>Medical menstrual regulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-49 years

          2. General good health

          3. Does not want to be pregnant

          4. Does not want to verify pregnancy status at the study site

          5. History of regular monthly menstrual cycles

          6. Missed menses of 1-21 days

          7. Sexual activity in the past 2 months

          8. Willing and able to sign consent forms

          9. Willing to provide urine sample at enrollment

         10. Willing to return for a follow-up visit

        Exclusion Criteria:

          1. Known allergies or contraindications to mifepristone and/or misoprostol

          2. Symptoms of or risk factors for ectopic pregnancy

          3. Current use of an IUD, contraceptive implant or injectable
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wendy R Sheldon, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wendy R Sheldon, PhD</last_name>
    <phone>212-448-1230</phone>
    <email>wsheldon@gynuity.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Carafem Health Center</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melissa Grant</last_name>
      <phone>855-729-2272</phone>
    </contact>
    <investigator>
      <last_name>Melissa Grant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carafem Health Center</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Grant</last_name>
      <phone>855-729-2272</phone>
    </contact>
    <investigator>
      <last_name>Melissa Grant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 28, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Sharing de-identified data will be considered upon individual request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

